Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
141 hedge funds and large institutions have $2.74B invested in Loxo Oncology, Inc in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 50 reducing their positions, and 32 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 50
1% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $17.2M
1% less capital invested
Capital invested by funds: $2.77B → $2.74B (-$33.5M)
5% less funds holding
Funds holding: 148 → 141 (-7)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$7.7B |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$189M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$85.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$62.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$32.2M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$19.5M |
| 4 |
Renaissance Technologies
New York
|
-$19.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$17.1M |
LOXO Hedge Fund Activity: Q4 2017 in Review
141 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2017, worth a combined $2.74B — down 1.2% from $2.77B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of LOXO and 25 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 53 added.
The largest buyer was OrbiMed, adding an estimated $7.7B. The largest seller was Aisling Capital, cutting an estimated $62.5M.
- 141 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2017, down from 148 in Q3 2017.
- Funds reported $2.74B of Loxo Oncology, Inc stock for Q4 2017, down 1.2% quarter-over-quarter.
- 25 funds opened new Loxo Oncology, Inc positions in Q4 2017 and 32 closed out, a net change of -7 holders.
- The largest Loxo Oncology, Inc buyer in Q4 2017 was OrbiMed, an estimated $7.7B added.
- The largest Loxo Oncology, Inc seller in Q4 2017 was Aisling Capital, an estimated $62.5M sold.
Based on aggregated 13F filings for Q4 2017.